What Is the GLP-1 Diet? The Hormone Behind the Search

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide lives in the PlexusDx Education Hub, where we unpack GLP-1 science, weight-management protocols, and the genetic factors behind metabolic decisions. Open the Education Hub

What people mean by the GLP-1 diet

The "GLP-1 diet" search is less about a meal plan and more about a hormone and the drug class that imitates it. To make sense of it, this article starts with what GLP-1 is biologically, then explains how receptor agonists work, which medications belong to the class, what they are approved for, their shared safety profile, and the genetic variables that sit upstream of every decision. Browse the Education Hub for related explainers.

What GLP-1 is as a hormone

Glucagon-like peptide-1 is an incretin hormone released by enteroendocrine L-cells in the small intestine after you eat. It prompts glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon from alpha cells, slows gastric emptying, and signals satiety in the hypothalamus. Native GLP-1 lasts only minutes in circulation because the enzyme DPP-4 breaks it down almost immediately, which is a central problem the medicines had to solve.

How receptor agonists solve the half-life problem

GLP-1 receptor agonists are peptides, and in emerging cases small molecules, engineered to engage the GLP-1 receptor while resisting DPP-4 degradation. That extends the half-life from minutes to hours or days and reproduces the hormone's effects at a pharmacological level: insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite through central satiety signaling. GIP/GLP-1 dual agonists such as tirzepatide add GIP receptor engagement for a second incretin mechanism.

Which medications belong to the class

As of April 2026, FDA-approved GLP-1 receptor agonists include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), the historically available lixisenatide (now discontinued in the U.S.), and semaglutide (Ozempic, Wegovy, Rybelsus). The GIP/GLP-1 dual agonist is tirzepatide (Mounjaro, Zepbound). The investigational triple agonist retatrutide, targeting GLP-1, GIP, and glucagon, has Phase 3 data but is not FDA-approved. Emerging oral non-peptide agonists such as orforglipron are in late-stage development.

What the class is approved to treat

Indications vary by product: type 2 diabetes for most, chronic weight management for Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for Ozempic, Trulicity, Victoza, and Rybelsus, and obstructive sleep apnea in adults with obesity for Zepbound as of December 2024. Certain products carry pediatric indications. FDA labeling governs what is prescribed for which indication, so discuss specifics with a provider.

The shared safety profile

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk seen in rodent studies. Contraindications include a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal and most pronounced during dose escalation, while serious events reported in clinical use include pancreatitis, gallbladder problems, and acute kidney injury with dehydration.

Why the mechanism is not a diet plan

It is worth naming directly: because GLP-1 agonists influence appetite, satiety, and gastric emptying, people sometimes describe the resulting eating pattern as a "diet." But the mechanism is pharmacological, not a menu, and it works by reproducing a hormone's signaling at a sustained level. Any changes to how you eat while on therapy should be guided by a qualified provider rather than a generic plan borrowed from the internet, since nutrition, medical history, and tolerance all interact with the medication's effects.

The genetic variable underneath

Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline appetite regulation and energy balance. They are pathway-level and do not predict response to any single compound, but they describe the terrain every GLP-1 medicine operates on. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across these systems, and PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols.

Frequently Asked Questions

Is the GLP-1 diet an actual eating plan?

Not really. The term usually refers to the GLP-1 hormone and the medications that mimic it rather than a specific menu. GLP-1 agonists influence appetite and satiety, which is why the phrase gets associated with eating patterns, but any nutrition plan should be discussed with a qualified healthcare provider.

What separates a GLP-1 agonist from a dual agonist?

A GLP-1 receptor agonist engages only the GLP-1 receptor. A GIP/GLP-1 dual agonist such as tirzepatide additionally engages the GIP receptor, adding a second incretin mechanism. Clinical trial programs including SURPASS and SURMOUNT suggest the dual mechanism may produce larger mean effects in some trial populations.

Who should avoid this drug class?

Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindicated across all FDA labels in the class. Those with severe gastrointestinal disease or a history of pancreatitis need careful clinical review, so discuss your full history with a provider.

Does genetics predict my GLP-1 results?

No. The Precision Peptide Genetic Test does not predict response to any compound in the class. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline energy-balance biology, giving upstream context that applies across every GLP-1 receptor agonist and dual agonist.

Keep reading across the PlexusDx Education Hub for more evidence-based GLP-1 and metabolic health explainers. Return to the Education Hub

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.